Recent Press Releases

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Brodalumab Meets All Primary and All Key Secondary Endpoints

THOUSAND OAKS, Calif. and LONDON,

Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 11, 2014

Improving how medicines are managed in the NHS

Improving how medicines are managed in the NHS The first research collaboration in the UK between a hospital, university and community pharmacist is taking place through a unique project from LJMU,...

FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab

FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that...

Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA)...

Actavis Names Maria Teresa Hilado Chief Financial Officer

Actavis Names Maria Teresa Hilado Chief Financial Officer - Expertise in global finance, M&A, business development - - Will join Actavis effective December 8, 2014 - DUBLIN, Nov. 10, 2014...

FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab

THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.

Health Care Facilities Stocks Review - HCA Holdings, Tenet Healthcare, Community Health Systems, Universal Health Services, and VCA Inc.

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 10, 2014

Lilly's Trulicity™ (dulaglutide) Now Available in U.S. Pharmacies

Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle

INDIANAPOLIS,

Dendreon Reaches Agreements on Terms of Financial Restructuring

Operations to Continue Without Interruption; PROVENGE® Remains Commercially Available Commences Voluntary Chapter 11 Proceedings to Implement Restructuring Agreements SEATTLE--(BUSINESS...

Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition

-- Further Strengthens Existing Pipeline to Address Infectious Diseases --

NEW BRUNSWICK, N.J., Nov.

Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal

Culinary Expert Visits Los Angeles on November 9 to Help Educate At-Risk Population About Ingredients for Successful Blood Sugar Management

Salix Pharmaceuticals Reports 3Q2014 Results

3Q14 Total Net Product Revenue Increases 49% Year-over-Year to $355 million 3Q14 EBITDA Increases 63% Year-over-Year to $161 million 3Q14 XIFAXAN® 550 Prescriptions Increase 23%...

Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors

Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors PITTSBURGH, Nov. 7, 2014 /PRNewswire/ -- Mylan Inc. (MYL)...

FRESENIUS KABI AND RUSSIAN PARTNERS TERMINATE JOINT VENTURE AGREEMENT

FRESENIUS KABI AND RUSSIAN PARTNERS TERMINATE JOINT VENTURE AGREEMENT November 06, 2014-Bad Homburg v.d.H. -- Fresenius Kabi and its partners Sistema JSFC and Zenitco Finance Management LLC have...

Amgen To Present At The Credit Suisse Annual Healthcare Conference

THOUSAND OAKS, Calif., Nov.

Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 6, 2014

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014

Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers<

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic...